Loading company…
Oncomatryx develops cancer therapies targeting the tumor microenvironment.
Oncomatryx is developing OMTX705 and antibody-drug conjugates for cancer treatment. OMTX705 entered clinical trials in 2022. The company is based in Derio, Spain, and is led by co-founders Laureano Simón and Manuel Sanz. In March 2026, it raised USD 67 million in series B funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in